Publications
Detailed Information
High serum TGF-alpha predicts poor response to lapatinib and capecitabine in HER2-positive breast cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Rhee, Jiyoung | - |
dc.contributor.author | Han, Sae-Won | - |
dc.contributor.author | Cha, Yongjun | - |
dc.contributor.author | Ham, Hye Seon | - |
dc.contributor.author | Kim, Hwang-phill | - |
dc.contributor.author | Oh, Do-Youn | - |
dc.contributor.author | Im, Seock-Ah | - |
dc.contributor.author | Park, Jong-Wan | - |
dc.contributor.author | Ro, Jungsil | - |
dc.contributor.author | Lee, Keun Seok | - |
dc.contributor.author | Park, In Hae | - |
dc.contributor.author | Im, Young-Hyuck | - |
dc.contributor.author | Bang, Yung-Jue | - |
dc.contributor.author | Kim, Tae-You | - |
dc.date.accessioned | 2021-01-31T11:03:35Z | - |
dc.date.available | 2021-01-31T11:03:35Z | - |
dc.date.created | 2020-07-23 | - |
dc.date.created | 2020-07-23 | - |
dc.date.created | 2020-07-23 | - |
dc.date.issued | 2011-01 | - |
dc.identifier.citation | Breast Cancer Research and Treatment, Vol.125 No.1, pp.107-114 | - |
dc.identifier.issn | 0167-6806 | - |
dc.identifier.other | 108438 | - |
dc.identifier.uri | https://hdl.handle.net/10371/172993 | - |
dc.description.abstract | Lapatinib and capecitabine combination therapy is effective in trastuzumab-resistant human epidermal growth factor receptor 2 (HER2)-positive breast cancer. We investigated the biomarkers from serum of patients receiving lapatinib and capecitabine Patients received lapatinib 1,250 mg once daily and capecitabine 2,000 mg/m(2)/day, day 1-14, every 3 weeks. Serum samples were obtained before treatment initiation. Levels of transforming growth factor-alpha (TGF-alpha), epidermal growth factor (EGF), extracellular domains of EGFR and HER2 were measured by enzyme-linked immunosorbent assay. The effect of TGF-alpha on in vitro sensitivity of SK-BR-3 cells to lapatinib was investigated. Sixty-four patients were included. Response rate was significantly higher in patients with low serum TGF-alpha (a parts per thousand currency sign3.75 pg/ml) compared to high TGF-alpha (> 3.75 pg/ml) [61.1% (11/18) vs. 17.4% (8/46), respectively; P = 0.001]. Low serum TGF-alpha was independently associated with better response in multivariate analysis [adjusted odds ratio, 8.96; 95% confidence interval (CI) 2.4-34.2]. Time-to-progression tended to be shorter in patients with high serum TGF-alpha compared to low TGF-alpha [median 3.8 months (95% CI 2.3-5.4) vs. 6.5 (95% CI 6.1-6.8), respectively; P = 0.067]. We confirmed that TGF-alpha diminished the sensitivity of SK-BR3-cells to lapatinib in vitro. The in vitro antiproliferative effect of cetuximab in combination with lapatinib was higher than that of lapatinib alone in SK-BR3-cells exposed to TGF-alpha. These data suggest that TGF-alpha plays a role in resistance to lapatinib and capecitabine therapy among HER2-positive breast cancer. | - |
dc.language | 영어 | - |
dc.publisher | Kluwer Academic Publishers | - |
dc.title | High serum TGF-alpha predicts poor response to lapatinib and capecitabine in HER2-positive breast cancer | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 임석아 | - |
dc.identifier.doi | 10.1007/s10549-010-1200-9 | - |
dc.citation.journaltitle | Breast Cancer Research and Treatment | - |
dc.identifier.wosid | 000284956400011 | - |
dc.identifier.scopusid | 2-s2.0-78651100870 | - |
dc.citation.endpage | 114 | - |
dc.citation.number | 1 | - |
dc.citation.startpage | 107 | - |
dc.citation.volume | 125 | - |
dc.identifier.sci | 000284956400011 | - |
dc.description.isOpenAccess | N | - |
dc.contributor.affiliatedAuthor | Oh, Do-Youn | - |
dc.contributor.affiliatedAuthor | Im, Seock-Ah | - |
dc.contributor.affiliatedAuthor | Park, Jong-Wan | - |
dc.contributor.affiliatedAuthor | Bang, Yung-Jue | - |
dc.contributor.affiliatedAuthor | Kim, Tae-You | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | GROWTH-FACTOR-ALPHA | - |
dc.subject.keywordPlus | TYROSINE KINASE INHIBITOR | - |
dc.subject.keywordPlus | ADJUVANT CHEMOTHERAPY | - |
dc.subject.keywordPlus | PROGNOSTIC-SIGNIFICANCE | - |
dc.subject.keywordPlus | PHASE-II | - |
dc.subject.keywordPlus | TRASTUZUMAB | - |
dc.subject.keywordPlus | CELLS | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | RECEPTOR | - |
dc.subject.keywordPlus | PLUS | - |
dc.subject.keywordAuthor | Breast cancer | - |
dc.subject.keywordAuthor | Lapatinib | - |
dc.subject.keywordAuthor | Transforming growth factor-alpha | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.